Brought to you by 
Akcea nets $133.7mm via IPO
01 Sep 2020
Executive Summary
After filing back in March, Ionis Pharmaceutical Inc.'s Akcea Therapeutics Inc. netted $133.7mm through an upsized initial public offering of 17.9mm common shares (including the overallotment) at $8 each. It planned to sell 9.6mm shares between $12 and $14. Ionis purchased 3.1mm shares in the IPO and will now own 68.3% of Akcea.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Antisense, Oligonucleotides
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Akcea nets $133.7mm via IPO
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice